^
Association details:
| Biomarker: | ALK V3a |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Published date:
12/03/2020
Excerpt:
A total of 51 patients who had received platinum plus pemetrexed were included for outcome analysis….Of note, patients with ALK V3a/b had a worse OS (HR 4.24 [95% CI 1.18–15.21], P = 0.026) (Fig. 3b). In multivariate analysis, ALK variant 3a/b remained an independent predictor of a poor OS (aHR 9.62 [95% CI 1.90–48.80], P = 0.006).
DOI:
10.1038/s41598-020-78152-1
